fluconazole has been researched along with Disseminated Trichosporonosis in 20 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Invasive trichosporonosis is a rare and lethal fungal infection that occurs in immunocompromised patients." | 5.62 | Successful Treatment of Breakthrough Trichosporon asahii Fungemia by the Combination Therapy of Fluconazole and Liposomal Amphotericin B in a Patient with Follicular Lymphoma. ( Itoh, K; Iwasaki, H; Negoro, E; Shigemi, H; Tokimatsu, I; Tsutani, H; Yamauchi, T, 2021) |
| "In this model, as the severity of trichosporonosis increased, higher doses of posaconazole were required to achieve equivalent activity levels." | 5.40 | Therapeutic efficacy of posaconazole in a murine model of disseminated trichosporonosis. ( González, GM; González, JG; Hernández-Bello, R; López, LJ; Palma-Nicolás, JP; Treviño-Rangel, Rde J, 2014) |
| "Most cases of deep-seated trichosporonosis develop in patients with neutropenia, but it has recently been reported that breakthrough infections with Trichosporon species can develop during the use of candin family of antifungal agents." | 2.52 | [Antifungal susceptibility and drug-resistant mechanism of Trichosporon]. ( Ishii, H; Kadota, J; Kushima, H; Tokimatsu, I, 2015) |
| "Trichosporon infections have been increasingly reported worldwide; however, little information is available either about their characteristics or the causative microorganism." | 1.91 | Aspects related to biofilm production and antifungal susceptibility of clinically relevant yeasts of the genus Trichosporon. ( Anversa, L; Arnoni, MV; Auler, M; Bonfietti, LX; de Camargo, BB; Dias, ALT; Garces, HG; Gimenes, VMF; Lara, BR; Leite Junior, DP; Melhem, MSC; Monari, GPM; Moreira, D; Oliveira, L; Paula, CR; Ramos, RTB; Richini-Pereira, VB; Ruiz, LDS; Silva, NC; Silveira, M, 2023) |
| "Invasive trichosporonosis is a rare and lethal fungal infection that occurs in immunocompromised patients." | 1.62 | Successful Treatment of Breakthrough Trichosporon asahii Fungemia by the Combination Therapy of Fluconazole and Liposomal Amphotericin B in a Patient with Follicular Lymphoma. ( Itoh, K; Iwasaki, H; Negoro, E; Shigemi, H; Tokimatsu, I; Tsutani, H; Yamauchi, T, 2021) |
| "Fluconazole was the most active drug among the antifungals tested." | 1.56 | Molecular Identification, Genotyping, Phenotyping, and Antifungal Susceptibilities of Medically Important Trichosporon, Apiotrichum, and Cutaneotrichosporon Species. ( da Costa, ARF; do Espírito Santo, EPT; Marques-da-Silva, SH; Monteiro, RC, 2020) |
| "In Asian countries, Trichosporon infection is a well-known disease in Japan." | 1.43 | Molecular characterisation and antifungal susceptibility of clinical Trichosporon isolates in India. ( Chakrabarti, A; Ghosh, A; Honnavar, P; Pamidi, U; Rastogi, V; Rudramurthy, SM, 2016) |
| "In this model, as the severity of trichosporonosis increased, higher doses of posaconazole were required to achieve equivalent activity levels." | 1.40 | Therapeutic efficacy of posaconazole in a murine model of disseminated trichosporonosis. ( González, GM; González, JG; Hernández-Bello, R; López, LJ; Palma-Nicolás, JP; Treviño-Rangel, Rde J, 2014) |
| "The etiology of all seven invasive trichosporonosis was T." | 1.38 | Susceptibilities to amphotericin B, fluconazole and voriconazole of Trichosporon clinical isolates. ( Cheng, MF; Hsieh, LY; Liou, CH; Lo, HJ; Lu, DC; Shi, ZY; Tsai, MS; Wang, AH; Wang, LS; Wu, CJ; Yang, YL, 2012) |
| "One patient developed trichosporonosis while on caspofungin and the other became infected/ colonised with Candida glabrata that was resistant to voriconazole and posaconazole." | 1.37 | Selection of resistant fungi in liver transplant recipients during use of newer antifungal agents -- a report of two cases. ( Lingegowda, PB; Tan, AL; Tan, BH; Tan, CK, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (65.00) | 24.3611 |
| 2020's | 7 (35.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kruschewsky, WLL | 1 |
| Massaroni-Peçanha, P | 1 |
| Maifrede, SB | 1 |
| Leite, MS | 1 |
| Pôssa, TAL | 1 |
| Alberto-Lei, F | 1 |
| Cayô, R | 1 |
| Peçanha, PM | 1 |
| Gonçalves, SS | 1 |
| Lara, BR | 1 |
| de Camargo, BB | 1 |
| Paula, CR | 1 |
| Monari, GPM | 1 |
| Garces, HG | 1 |
| Arnoni, MV | 1 |
| Silveira, M | 1 |
| Gimenes, VMF | 1 |
| Leite Junior, DP | 1 |
| Bonfietti, LX | 1 |
| Oliveira, L | 1 |
| Melhem, MSC | 1 |
| Auler, M | 1 |
| Ramos, RTB | 1 |
| Dias, ALT | 1 |
| Silva, NC | 1 |
| Moreira, D | 1 |
| Richini-Pereira, VB | 1 |
| Anversa, L | 1 |
| Ruiz, LDS | 1 |
| do Espírito Santo, EPT | 1 |
| Monteiro, RC | 1 |
| da Costa, ARF | 1 |
| Marques-da-Silva, SH | 1 |
| Monzani, V | 1 |
| Córdoba, S | 1 |
| Vivot, M | 1 |
| Arias, B | 1 |
| Vivot, W | 1 |
| Szusz, W | 1 |
| Castellaro, P | 1 |
| Appendino, A | 1 |
| Taverna, CG | 1 |
| Sadamatsu, H | 1 |
| Takahashi, K | 1 |
| Tashiro, H | 1 |
| Ogusu, S | 1 |
| Haraguchi, T | 1 |
| Nakashima, C | 1 |
| Nakamura, T | 1 |
| Sueoka-Aragane, N | 1 |
| Matsumoto, Y | 1 |
| Yamazaki, H | 1 |
| Yamasaki, Y | 1 |
| Tateyama, Y | 1 |
| Yamada, T | 1 |
| Sugita, T | 2 |
| Itoh, K | 1 |
| Iwasaki, H | 1 |
| Negoro, E | 1 |
| Shigemi, H | 1 |
| Tokimatsu, I | 2 |
| Tsutani, H | 1 |
| Yamauchi, T | 1 |
| Nath, R | 1 |
| Sargiary, P | 1 |
| Borkakoty, B | 1 |
| Parida, P | 1 |
| Francisco, EC | 1 |
| de Almeida Junior, JN | 1 |
| de Queiroz Telles, F | 1 |
| Aquino, VR | 1 |
| Mendes, AVA | 1 |
| de Andrade Barberino, MGM | 1 |
| de Tarso O Castro, P | 1 |
| Guimarães, T | 1 |
| Hahn, RC | 1 |
| Padovan, ACB | 1 |
| Chaves, GM | 1 |
| Colombo, AL | 1 |
| Sasai, D | 1 |
| Okubo, Y | 1 |
| Ishiwatari, T | 1 |
| Kaneko, T | 1 |
| Murayama, SY | 1 |
| Shimamura, T | 1 |
| Shinozaki, M | 1 |
| Hasegawa, C | 1 |
| Mitsuda, A | 1 |
| Tochigi, N | 1 |
| Wakayama, M | 1 |
| Nemoto, T | 1 |
| Shibuya, K | 1 |
| Rastogi, V | 2 |
| Rudramurthy, SM | 2 |
| Maheshwari, M | 1 |
| Nirwan, PS | 1 |
| Chakrabarti, A | 2 |
| Batra, S | 1 |
| Treviño-Rangel, Rde J | 1 |
| López, LJ | 1 |
| Palma-Nicolás, JP | 1 |
| Hernández-Bello, R | 1 |
| González, JG | 1 |
| González, GM | 1 |
| Mariné, M | 1 |
| Bom, VL | 1 |
| de Castro, PA | 1 |
| Winkelstroter, LK | 1 |
| Ramalho, LN | 1 |
| Brown, NA | 1 |
| Goldman, GH | 1 |
| Mohd Tap, R | 1 |
| Sabaratnam, P | 1 |
| Ramli, NY | 1 |
| Hashim, R | 1 |
| Mohd Fuat, AR | 1 |
| Ng, PP | 1 |
| Khairam, H | 1 |
| Ahmad, N | 1 |
| Kushima, H | 1 |
| Ishii, H | 1 |
| Kadota, J | 1 |
| Honnavar, P | 1 |
| Pamidi, U | 1 |
| Ghosh, A | 1 |
| Moreno-Coutiño, G | 1 |
| Aquino, MA | 1 |
| Vega-Memije, M | 1 |
| Arenas, R | 1 |
| Lingegowda, PB | 1 |
| Tan, CK | 1 |
| Tan, AL | 1 |
| Tan, BH | 1 |
| Tsai, MS | 1 |
| Yang, YL | 1 |
| Wang, AH | 1 |
| Wang, LS | 1 |
| Lu, DC | 1 |
| Liou, CH | 1 |
| Hsieh, LY | 1 |
| Wu, CJ | 1 |
| Cheng, MF | 1 |
| Shi, ZY | 1 |
| Lo, HJ | 1 |
| Singla, N | 1 |
| Gulati, N | 1 |
| Kaistha, N | 1 |
| Chander, J | 1 |
2 reviews available for fluconazole and Disseminated Trichosporonosis
| Article | Year |
|---|---|
Subcutaneous Infection Associated with Trichosporon ovoides: A Case Report and Review of Literature.
Topics: Antifungal Agents; Dermatomycoses; DNA, Intergenic; Female; Fluconazole; Humans; Immunocompromised H | 2016 |
[Antifungal susceptibility and drug-resistant mechanism of Trichosporon].
Topics: Antifungal Agents; Azoles; Drug Resistance, Fungal; Fluconazole; Microbial Sensitivity Tests; Neutro | 2015 |
18 other studies available for fluconazole and Disseminated Trichosporonosis
| Article | Year |
|---|---|
Trichosporon asahii causing subcutaneous mycoses in an immunocompetent patient: case report and a minireview.
Topics: Antifungal Agents; Azoles; Basidiomycota; Dermatomycoses; Fluconazole; Humans; Trichosporon; Trichos | 2022 |
Aspects related to biofilm production and antifungal susceptibility of clinically relevant yeasts of the genus Trichosporon.
Topics: Amphotericin B; Animals; Antifungal Agents; Biofilms; Caspofungin; Fluconazole; Humans; Itraconazole | 2023 |
Molecular Identification, Genotyping, Phenotyping, and Antifungal Susceptibilities of Medically Important Trichosporon, Apiotrichum, and Cutaneotrichosporon Species.
Topics: Antifungal Agents; Basidiomycota; Biofilms; Brazil; DNA, Ribosomal Spacer; Fluconazole; Fungal Prote | 2020 |
A case report of catheter-related bloodstream infection due to Trichosporon coremiiforme in a patient with secondary neutropenia to HIV.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antitubercular Agents; Bacteremia; Catheter-R | 2020 |
A rare case of Trichosporon mycotoxinivorans and Cryptococcus neoformans co-infection in lung.
Topics: Aged; Antifungal Agents; Biopsy; Bronchoalveolar Lavage Fluid; Coinfection; Cryptococcosis; Cryptoco | 2020 |
A novel silkworm infection model with fluorescence imaging using transgenic Trichosporon asahii expressing eGFP.
Topics: Amphotericin B; Animals; Antifungal Agents; Bombyx; Disease Models, Animal; Fluconazole; Green Fluor | 2020 |
Successful Treatment of Breakthrough Trichosporon asahii Fungemia by the Combination Therapy of Fluconazole and Liposomal Amphotericin B in a Patient with Follicular Lymphoma.
Topics: Amphotericin B; Antifungal Agents; Basidiomycota; Fluconazole; Fungemia; Humans; Lymphoma, Follicula | 2021 |
Cutaneotrichosporon (Trichosporon) debeurmannianum: A Rare Yeast Isolated from Blood and Urine Samples.
Topics: Adolescent; Adult; Antifungal Agents; Blood; Child, Preschool; Cluster Analysis; Disk Diffusion Anti | 2018 |
Species distribution and antifungal susceptibility of 358 Trichosporon clinical isolates collected in 24 medical centres.
Topics: Amphotericin B; Antifungal Agents; Brazil; DNA, Fungal; DNA, Ribosomal; Drug Resistance, Fungal; Flu | 2019 |
Histopathological evaluation of the efficacy of antifungals for experimental Trichosporon bloodstream infection.
Topics: Amphotericin B; Animals; Antifungal Agents; Colony Count, Microbial; Disease Models, Animal; Flucona | 2013 |
Non-healing ulcer due to Trichosporon loubieri in an immunocompetent host and review of published reports.
Topics: Antifungal Agents; Debridement; DNA, Fungal; DNA, Ribosomal; DNA, Ribosomal Spacer; Female; Fluconaz | 2013 |
Therapeutic efficacy of posaconazole in a murine model of disseminated trichosporonosis.
Topics: Administration, Oral; Amphotericin B; Animals; Antifungal Agents; Colony Count, Microbial; Fluconazo | 2014 |
The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
Topics: Amphotericin B; Animals; Antifungal Agents; Caspofungin; Disease Models, Animal; Drug Resistance, Fu | 2015 |
Molecular characterisation and antifungal susceptibility of clinical Trichosporon isolates in India.
Topics: Amphotericin B; Antifungal Agents; Female; Fluconazole; Genotype; Humans; India; Itraconazole; Male; | 2016 |
Necrotic ulcer caused by Trichosporon asahii in an immunocompetent adolescent.
Topics: Adolescent; Dermatomycoses; Fluconazole; Humans; Immunocompetence; Male; Necrosis; Trichosporon; Tri | 2012 |
Selection of resistant fungi in liver transplant recipients during use of newer antifungal agents -- a report of two cases.
Topics: Adult; Antifungal Agents; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fatal Outcome; Female | 2011 |
Susceptibilities to amphotericin B, fluconazole and voriconazole of Trichosporon clinical isolates.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Fluconazole; Humans; Male; Microbial Sensitivity Tes | 2012 |
Candida colonization in urine samples of ICU patients: determination of etiology, antifungal susceptibility testing and evaluation of associated risk factors.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Candida; Candidiasis; Female; Fluconazol | 2012 |